BTCA — Bactolac Pharmaceutical Share Price
Last trade - 00:00- $1.14bn
- $1.14bn
- $22.93m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 78.68 | ||
| Price to Tang. Book | 164.17 | ||
| Price to Free Cashflow | 441.05 | ||
| Price to Sales | 42.83 | ||
| EV to EBITDA | 327.7 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 21.36% | ||
| Return on Equity | 11.82% | ||
| Operating Margin | 13.1% | ||
Financial Summary
| Year End 30th Sep | Unit | 2001 | 2002 | 2003 | 2004 | 2005 | 2006E | 2007E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 17.61 | 21.63 | 12.79 | 17.64 | 22.93 | n/a | n/a | 7.37% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | +95.48 | -56.91 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bactolac Pharmaceutical, Inc. is a nutraceutical company. The Company is specialized in full turn-key nutritional supplement and vitamin contract manufacturing. As a dietary supplement manufacturer, the Company has full-service health supplement facilities. It is involved in product development and manufacturing, product testing, and packaging and label application. The Company’s services include vitamin manufacturing contract/private label manufacturing, herbal supplement manufacturing, nutritional supplements manufacturing, sports supplement manufacturing, greens and berry powders, pet supplement manufacturing, protein powder manufacturing, supplement testing lab, and contract food manufacturing. The Company’s 350,000 square feet facility is Current Good Manufacturing Practice (cGMP) certified. Its facility houses a micro-laboratory and an analytical laboratory, where the Company conducts comprehensive tests on all materials and final products.
Directors
- Pailla Reddy CHM (50)
- Gregory Pusey PRE
- Jeffrey McGonegal SVF (70)
- F. Wayne Ballenger DRC (63)
- Randall Humphreys DRC (57)
- David Welch DRC (73)
- Last Annual
- September 30th, 2005
- Last Interim
- June 30th, 2006
- Incorporated
- February 28th, 2000
- Public Since
- July 15th, 1994
- No. of Shareholders
- 2,500
- No. of Employees
- 125
- Sector
- Food & Tobacco
- Industry
- Consumer Defensives
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 9,523
- Address
- 7 Oser Ave, HAUPPAUGE, 11788-3811
- Web
- https://bactolac.com/
- Phone
- +1 6319514908
- Auditors
- Gelfond Hochstadt Pangburn Stark & Co.
Upcoming Events for BTCA
Similar to BTCA
Adia Nutrition
Pink Sheets on Nasdaq
Agri-Dynamics
Pink Sheets on Nasdaq
Agristar
Pink Sheets on Nasdaq
Aifarm
Pink Sheets on Nasdaq
AiXin Life International
Pink Sheets on Nasdaq
FAQ
As of Today at 18:03 UTC, shares in Bactolac Pharmaceutical are trading at $120,000.00. This share price information is delayed by 15 minutes.
Shares in Bactolac Pharmaceutical last closed at $120,000.00 and the price had moved by -9.06% over the past 365 days. In terms of relative price strength the Bactolac Pharmaceutical share price has underperformed the S&P500 Index by -17.71% over the past year.
There is no consensus recommendation for this security.
Bactolac Pharmaceutical does not currently pay a dividend.
Bactolac Pharmaceutical does not currently pay a dividend.
Bactolac Pharmaceutical does not currently pay a dividend.
To buy shares in Bactolac Pharmaceutical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $120,000.00, shares in Bactolac Pharmaceutical had a market capitalisation of $1.14bn.
Here are the trading details for Bactolac Pharmaceutical:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: BTCA
Based on an overall assessment of its quality, value and momentum Bactolac Pharmaceutical is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bactolac Pharmaceutical. Over the past six months, its share price has underperformed the S&P500 Index by -12.52%.
As of the last closing price of $120,000.00, shares in Bactolac Pharmaceutical were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Bactolac Pharmaceutical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $120,000.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Bactolac Pharmaceutical's management team is headed by:
- Pailla Reddy - CHM
- Gregory Pusey - PRE
- Jeffrey McGonegal - SVF
- F. Wayne Ballenger - DRC
- Randall Humphreys - DRC
- David Welch - DRC